The peptide therapeutics landscape continues to evolve at a rapid pace, with pharmaceutical companies now developing once-monthly injectable formulations that could revolutionize obesity treatment. According to The Manila Times, Ascletis Pharma has submitted two Investigational New Drug (IND) applications to the U.S. FDA for novel peptide-based obesity treatments: ASC36, a once-monthly amylin receptor agonist, and ASC36_35 FDC, a co-formulated combination therapy incorporating both amylin and dual GLP-1R/GIPR receptor agonists.
This development represents a significant advancement in the peptide space that Tony Huge and the broader biohacking community have been monitoring closely. As peptide therapies transition from experimental compounds used by bodybuilders and performance enhancement enthusiasts to FDA-regulated pharmaceutical products, the implications for body composition optimization, metabolic health, and longevity protocols are substantial.
Understanding the New Peptide Obesity Treatments
Ascletis’s dual submission to the FDA signals a strategic approach to obesity management through peptide-based therapeutics. The first candidate, ASC36, targets the amylin receptor pathway—a mechanism that has garnered increasing attention in metabolic research circles familiar to those following Tony Huge’s content on peptide applications.
Amylin is a naturally occurring peptide hormone co-secreted with insulin from pancreatic beta cells. It plays a crucial role in regulating glucose metabolism, slowing gastric emptying, and promoting satiety. By developing a synthetic amylin receptor agonist that requires only monthly administration, Ascletis is addressing one of the primary barriers to peptide therapy adoption: injection frequency.
The second application, ASC36_35 FDC (Fixed-Dose Combination), represents an even more sophisticated approach by combining the amylin receptor agonist with a dual GLP-1R/GIPR agonist in a single monthly injection. This combination therapy leverages multiple metabolic pathways simultaneously, potentially offering superior efficacy compared to monotherapy approaches.
The Peptide Revolution: From Underground to Mainstream
The bodybuilding and biohacking communities—areas where Tony Huge has established significant expertise—have experimented with peptide compounds for years, often obtaining these substances through research chemical suppliers or international sources. Peptides like CJC-1295, Ipamorelin, BPC-157, and various growth hormone secretagogues have been staples in performance enhancement and recovery protocols.
Now, pharmaceutical companies are bringing properly researched, clinically validated peptide therapies through the regulatory pathway. This transition has several implications for the community that follows Tony Huge’s work:
Validation of Peptide Mechanisms
The FDA submission of these peptide-based obesity treatments validates what experimental users have known for years: peptides can dramatically influence body composition, metabolic function, and weight management. While previous generations of peptides were used primarily for muscle building and recovery, these new obesity-focused compounds demonstrate the broader therapeutic potential of peptide science.
Enhanced Safety Profiles
Pharmaceutical-grade peptides that undergo rigorous clinical trials will provide better safety data, more consistent formulations, and clearer dosing protocols compared to research-grade compounds. For the biohacking community interested in body optimization, this represents an opportunity to access peptide therapies with established safety parameters.
GLP-1 Receptor Agonists: The Current Gold Standard
The inclusion of a GLP-1R/GIPR dual agonist in the ASC36_35 FDC formulation aligns with current pharmaceutical trends. Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have demonstrated remarkable efficacy for weight loss, with some patients experiencing 15-20% body weight reduction.
These GLP-1 receptor agonists work by:
- Enhancing insulin secretion in response to meals
- Reducing glucagon release, which lowers blood sugar
- Slowing gastric emptying to increase satiety
- Acting on brain centers that regulate appetite
The addition of GIP (glucose-dependent insulinotropic polypeptide) receptor agonism, as seen in tirzepatide and now potentially in ASC36_35 FDC, appears to enhance weight loss efficacy beyond GLP-1 agonism alone. The bodybuilding community has taken notice, with some athletes incorporating these peptides during cutting phases—though Tony Huge has documented both the benefits and potential downsides of such applications in his educational content.
Monthly Dosing: A Game-Changer for Compliance
One of the most significant innovations in these new Ascletis formulations is the once-monthly dosing schedule. Current GLP-1 receptor agonists require weekly injections, while many peptides used in bodybuilding and biohacking protocols require daily or even multiple daily injections.
Monthly administration offers several advantages:
- Improved adherence: Fewer injections mean better patient compliance over extended periods
- Stable blood levels: Extended-release formulations can provide more consistent peptide concentrations
- Reduced injection site reactions: Less frequent administration may minimize local tissue irritation
- Lifestyle convenience: Monthly dosing better fits busy schedules and reduces the psychological burden of daily protocols
For individuals following comprehensive biohacking protocols—as often discussed in Tony Huge’s content—reducing injection frequency while maintaining efficacy represents a significant quality-of-life improvement, especially when combining multiple therapeutic interventions.
Key Takeaways
- Ascletis Pharma has submitted two IND applications to the FDA for novel monthly peptide obesity treatments: ASC36 (amylin receptor agonist) and ASC36_35 FDC (combination therapy)
- The ASC36_35 FDC combines amylin receptor agonism with dual GLP-1R/GIPR agonism in a single monthly injection
- Once-monthly dosing represents a significant advancement over current weekly GLP-1 medications like semaglutide and tirzepatide
- These pharmaceutical developments validate peptide mechanisms that the bodybuilding and biohacking communities have explored for years
- The transition of peptides from research compounds to FDA-regulated therapies provides enhanced safety data and quality control
- Combination peptide therapies targeting multiple metabolic pathways may offer superior efficacy for body composition optimization
- Tony Huge’s audience interested in cutting-edge body optimization strategies should monitor the clinical development of these compounds
Implications for Bodybuilding and performance enhancement
While these peptide formulations target obesity treatment specifically, the bodybuilding community has historically adopted medical therapies for body composition purposes. GLP-1 agonists have already appeared in competitive bodybuilding prep protocols, and the addition of amylin receptor agonism could provide complementary benefits.
Amylin’s effects on appetite suppression and metabolic rate may prove useful during cutting phases, though the dramatic weight loss associated with these medications must be carefully managed to preserve lean muscle mass. Tony Huge has emphasized in his educational content that aggressive fat loss protocols without adequate protein intake and resistance training can lead to significant muscle catabolism.
The monthly dosing schedule, while convenient for general populations, may present challenges for bodybuilders seeking precise control over their contest prep timeline. Weekly or daily peptide protocols allow more granular adjustment based on physique progression and show date.
The Future of Peptide Therapeutics
Ascletis’s FDA submissions represent just one chapter in the ongoing peptide therapeutics story. Pharmaceutical investment in peptide research continues to accelerate, with numerous companies developing novel peptide sequences targeting everything from metabolic disorders to longevity pathways.
For the biohacking community that follows Tony Huge’s work, this pharmaceutical interest validates the potential of peptide-based interventions while simultaneously raising questions about access, cost, and the future of research peptides. As more compounds move through clinical trials and regulatory approval, the distinction between pharmaceutical peptides and research chemicals will become increasingly important.
Conclusion
The submission of ASC36 and ASC36_35 FDC to the FDA marks another milestone in the evolution of peptide-based obesity treatment. By combining amylin receptor agonism with dual GLP-1R/GIPR agonism in a convenient monthly formulation, Ascletis is pushing the boundaries of metabolic therapeutics. For those following Tony Huge’s coverage of peptides, SARMs, and body optimization strategies, these developments underscore the growing mainstream acceptance of peptide science while highlighting the ongoing innovation in compounds that influence body composition, metabolic health, and longevity. As these therapies progress through clinical trials, the bodybuilding and biohacking communities will undoubtedly monitor their potential applications beyond conventional obesity treatment.
Frequently Asked Questions
What is ASC36 and how does it treat obesity?
ASC36 is a novel peptide-based obesity treatment developed by Ascletis Pharma. It functions as an amylin receptor agonist, mimicking the natural hormone amylin to regulate appetite and glucose metabolism. Administered as a once-monthly injection, it targets weight management through appetite suppression and improved metabolic control, offering a convenient alternative to weekly GLP-1 medications.
How often do you inject monthly peptide obesity treatments?
Monthly peptide injections like ASC36 are administered once every 30 days, significantly reducing injection frequency compared to weekly alternatives such as semaglutide or tirzepatide. This reduced dosing schedule improves patient compliance and convenience while maintaining consistent therapeutic levels throughout the month for sustained weight management benefits.
Are monthly peptide injections for weight loss FDA approved?
As of now, monthly peptide obesity treatments like ASC36 are still in development stages. Ascletis Pharma has submitted IND applications to the FDA, meaning clinical trials are underway. These formulations are not yet approved for clinical use, and patients should consult healthcare providers about currently available FDA-approved obesity medications.